Nasdaq · Biotech stocks database
LENZ (LENZ Therapeutics Inc.) stock: $4.23, $133.5M market cap, $197.3M cash, -$63.8M EV, $159.4M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve vision. On July 31, 2025, the United States (“U.S.”) Food and Drug Administration (“FDA”) approved VIZZ ® (aceclidine ophthalmic solution) 1.44%, formerly known as LNZ100, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the U.S.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $197.3M |
|---|---|
| Debt | $0.0M |
| Net cash | $197.3M |
| Enterprise value | -$63.8M |
| Basic shares | 31.4M shares |
| Fully diluted shares | 37.7M shares |
| Fully diluted market cap | $159.4M |
| Cash per share | $6.28 |
| Quarterly burn | $38.7M |
| Cash runway | 5.1 quarters |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-11.
Cap table as of 2026-06-30.
Loading LENZ daily closes…